



PROFILES OF ANTIDIABETIC MEDICATIONS



	MET	GLP-1 RA	SGLT-2i	DPP-4i	AGi	TZD (moderate dose)	SU GLN	COLSVL	BCR-QR	INSULIN	PRAML
HYPO	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral	Moderate/ Severe Mild	Neutral	Neutral	Moderate to Severe	Neutral
WEIGHT	Slight Loss	Loss	Loss	Neutral	Neutral	Gain	Gain	Neutral	Neutral	Gain	Loss
RENAL / GU	Contraindicated if eGFR < 30 mL/min/1.73 m ²	Exenatide Not Indicated CrCl < 30	Not Indicated for eGFR < 45 mL/min/1.73 m ² Genital Mycotic Infections	Dose Adjustment Necessary (Except Linagliptin) Effective in Reducing Albuminuria	Neutral	Neutral	More Hypo Risk	Neutral	Neutral	More Hypo Risk	Neutral
		Possible Benefit of Liraglutide	Possible Benefit of Empagliflozin								
GI Sx	Moderate	Moderate	Neutral	Neutral	Moderate	Neutral	Neutral	Mild	Moderate	Neutral	Moderate
CHF	Neutral	Possible Benefit of Liraglutide	Possible Benefit of Empagliflozin	Possible Risk for Saxagliptin and Alogliptin	Neutral	Moderate	More CHF Risk	Neutral	Neutral	More CHF Risk	Neutral
CARDIAC*			Possible CV Benefit	Possible CV Benefit		Neutral	May Reduce Stroke Risk	?	Benefit	Safe	
ASCVD											
BONE	Neutral	Neutral	Canagliflozin Warning	Neutral	Neutral	Moderate Fracture Risk	Neutral	Neutral	Neutral	Neutral	Neutral
KETOACIDOSIS	Neutral	Neutral	DKA Occurring in T2D in Various Stress Settings	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral

■ Few adverse events or possible benefits
 ■ Use with caution
 ■ Likelihood of adverse effects
 ? Uncertain effect
 * FDA indication to prevent CVD death in diabetes plus prior CVD events